Literature DB >> 9228507

Basic science and clinical utility of biochemical markers of bone turnover--a Congress report.

M J Seibel1, D J Baylink, J R Farley, S Epstein, M Yamauchi, R Eastell, H A Pols, L G Raisz, C M Gundberg.   

Abstract

Keywords:  Non-programmatic

Mesh：

Substances：

Year:  1997        PMID： 9228507     DOI： 10.1055/s-0029-1211740

Source DB:  PubMed          Journal:  Exp Clin Endocrinol Diabetes        ISSN： 0947-7349            Impact factor:   2.949


× No keyword cloud information.
  3 in total

1.  Odanacatib, a selective cathepsin K inhibitor to treat osteoporosis: safety, tolerability, pharmacokinetics and pharmacodynamics--results from single oral dose studies in healthy volunteers.

Authors:  S Aubrey Stoch; Stefan Zajic; Julie A Stone; Deborah L Miller; Lucas van Bortel; Kenneth C Lasseter; Barnali Pramanik; Caroline Cilissen; Qi Liu; Lida Liu; Boyd B Scott; Deborah Panebianco; Yu Ding; Keith Gottesdiener; John A Wagner
Journal:  Br J Clin Pharmacol       Date:  2013-05       Impact factor: 4.335

2.  [Biochemical bone resorption markers during the healing of osteoporotic fractures].

Authors:  C Heiss; L M Hoesel; M Pausch; S A Meissner; U Horas; O Kilian; U Wehr; W A Rambeck; R Schnettler
Journal:  Unfallchirurg       Date:  2008-09       Impact factor: 1.000

Review 3.  Clinical and translational pharmacology of the cathepsin K inhibitor odanacatib studied for osteoporosis.

Authors:  Julie A Stone; Jacqueline B McCrea; Rose Witter; Stefan Zajic; S Aubrey Stoch
Journal:  Br J Clin Pharmacol       Date:  2019-03-18       Impact factor: 4.335
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.